Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis.
作者信息
Bresnihan B
机构信息
St Vincent's University Hospital, Dublin 4, Republic of Ireland.
出版信息
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii74-7. doi: 10.1136/ard.61.suppl_2.ii74.
Abstract
摘要
相似文献
1
Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis.阿那白滞素对类风湿关节炎临床和影像学结局的影响。
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii74-7. doi: 10.1136/ard.61.suppl_2.ii74.
2
Anakinra shows promise for treating patients with rheumatoid arthritis.阿那白滞素在治疗类风湿性关节炎患者方面显示出前景。
J Am Pharm Assoc (Wash). 2002 Jul-Aug;42(4):660-2. doi: 10.1331/108658002763029661.
3
Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist.用白细胞介素1受体拮抗剂治疗类风湿性关节炎。
Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I96-8. doi: 10.1136/ard.58.2008.i96.
4
Clinical and radiological effects of anakinra in patients with rheumatoid arthritis.阿那白滞素对类风湿关节炎患者的临床及影像学影响。
Rheumatology (Oxford). 2003 May;42 Suppl 2:ii22-8. doi: 10.1093/rheumatology/keg329.
5
The trials of anakinra.阿那白滞素的试验
Lancet. 2004;364(9437):827-8. doi: 10.1016/S0140-6736(04)16999-7.
6
7
Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis.阿那白滞素（白细胞介素-1受体拮抗剂）对类风湿关节炎患者的功能和生活质量有积极影响。
Adv Ther. 2006 Mar-Apr;23(2):208-17. doi: 10.1007/BF02850127.
8
9
[The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis].白细胞介素-1受体拮抗剂（阿那白滞素）治疗类风湿关节炎的安全性
Reumatismo. 2004 Jan-Mar;56(1 Suppl 1):74-9. doi: 10.4081/reumatismo.2004.1s.74.
10
[Anakinra for therapy of rheumatoid arthritis].[阿那白滞素用于类风湿关节炎的治疗]
Nihon Rinsho. 2005 Jan;63 Suppl 1:534-7.
引用本文的文献
1
Anakinra for rheumatoid arthritis.阿那白滞素用于治疗类风湿关节炎。
Cochrane Database Syst Rev. 2009 Jan 21(1):CD005121. doi: 10.1002/14651858.CD005121.pub3.
2
Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.依那西普治疗类风湿关节炎：一年超声临床随访
Clin Rheumatol. 2008 Apr;27(4):491-6. doi: 10.1007/s10067-007-0738-3. Epub 2007 Oct 19.
3
Management of sight-threatening uveitis: new therapeutic options.威胁视力的葡萄膜炎的管理：新的治疗选择。
Drugs. 2005;65(4):497-519. doi: 10.2165/00003495-200565040-00005.
4
Induction of vascular endothelial growth factor and matrix metalloproteinase-3 (stromelysin) by interleukin-1 in human articular chondrocytes and synoviocytes.白细胞介素-1对人关节软骨细胞和滑膜细胞中血管内皮生长因子及基质金属蛋白酶-3（基质溶解素）的诱导作用
Rheumatol Int. 2005 Dec;26(2):93-8. doi: 10.1007/s00296-004-0513-6. Epub 2004 Sep 29.
5
The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.来氟米特的活性代谢产物A77 1726可增加人滑膜成纤维细胞和关节软骨细胞中白细胞介素-1受体拮抗剂的产生。
Arthritis Res Ther. 2004;6(3):R181-9. doi: 10.1186/ar1157. Epub 2004 Feb 19.
本文引用的文献
1
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.重组人白细胞介素-1受体拮抗剂阿那白滞素联合甲氨蝶呤治疗类风湿关节炎：一项为期24周的多中心、随机、双盲、安慰剂对照试验的结果。
Arthritis Rheum. 2002 Mar;46(3):614-24. doi: 10.1002/art.10141.
2
Anti-interleukin-1 therapy in rheumatic diseases.抗白细胞介素-1疗法在风湿性疾病中的应用。
Curr Opin Rheumatol. 2001 May;13(3):170-6. doi: 10.1097/00002281-200105000-00004.
3
The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1.白细胞介素-1受体拮抗剂在阻断由白细胞介素-1介导的炎症中的作用。
N Engl J Med. 2000 Sep 7;343(10):732-4. doi: 10.1056/NEJM200009073431011.
4
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.一项关于重组人白细胞介素-1受体拮抗剂治疗类风湿关节炎患者的多中心、双盲、剂量范围、随机、安慰剂对照研究：影像学进展及Genant和Larsen评分的相关性
Arthritis Rheum. 2000 May;43(5):1001-9. doi: 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P.
5
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.重组人白细胞介素-1受体拮抗剂治疗类风湿关节炎
Arthritis Rheum. 1998 Dec;41(12):2196-204. doi: 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2.
6
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.美国风湿病学会类风湿关节炎临床试验疾病活动度测量初步核心指标集。类风湿关节炎临床试验结果测量委员会。
Arthritis Rheum. 1993 Jun;36(6):729-40. doi: 10.1002/art.1780360601.
7
Measurement of patient outcome in arthritis.关节炎患者预后的测量
Arthritis Rheum. 1980 Feb;23(2):137-45. doi: 10.1002/art.1780230202.
Zotero 插件